ANL logo

ANL Stock

Profile

Full Name:

Adlai Nortye Ltd.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Cayman Islands

IPO:

23 September 2023

Indexes:

Not included

Description:

Adlai Nortye American Depositary Shares (ANL) focuses on developing innovative cancer therapies. The company specializes in creating treatments for various types of cancer, aiming to improve patient outcomes through advanced research and development in oncology.

Events Calendar

Earnings

Next earnings date:

Aug 08, 2025

Recent quarterly earnings:

Aug 08, 2024

Recent annual earnings:

Apr 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

11 Nov '24 HC Wainwright & Co.
Buy
18 Oct '24 HC Wainwright & Co.
Buy
04 Sept '24 HC Wainwright & Co.
Buy
20 June '24 Cantor Fitzgerald
Overweight
24 Oct '23 Cantor Fitzgerald
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Adlai Nortye Ltd. Sponsored ADR (ANL) Loses -33.06% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Adlai Nortye Ltd. Sponsored ADR (ANL) Loses -33.06% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Adlai Nortye Ltd. Sponsored ADR (ANL) Loses -33.06% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ANL
zacks.com09 September 2024

Adlai Nortye Ltd. Sponsored ADR (ANL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
ANL
globenewswire.com23 May 2024

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
ANL
globenewswire.com22 May 2024

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, recently announced that the first patient was dosed in the Phase II clinical trial known as ARTEMIS (Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery). This clinical study evaluates palupiprant (AN0025), a small molecule prostaglandin E receptor 4 (“EP4”) antagonist, with chemoradiotherapy and radiotherapy (total neoadjuvant therapy: ‘TNT') (“CRT”) for the treatment of rectal cancer. The study has been developed and is being led by the Cancer Research (“CRUK”) Clinical Trials Unit (“CTU”) at the University of Leeds, with clinical leadership teams from consultant oncologists Prof Simon Gollins and Prof Mark Saunders.

Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year?
Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year?
Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year?
ANL
Zacks Investment Research15 May 2024

This is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Boston Scientific (BSX) have fared in comparison to their industry in the current year.

Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
ANL
Zacks Investment Research25 April 2024

Adlai Nortye Ltd. Sponsored ADR (ANL) and Elevance Health (ELV) have outperformed their sector year-to-date.

U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline
U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline
U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline
ANL
Seeking Alpha30 September 2023

The third quarter wrapped up with four IPOs and eight pipeline additions. Eight issuers submitted initial filings this past week. The October IPO market looks like it will be off to a quiet start, with no IPOs currently scheduled for the week ahead.

U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices
U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices
U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices
ANL
Seeking Alpha12 August 2023

Three small issuers began trading this past week, two of which were eligible for inclusion in our IPO stats. While most IPOs are biding their time through the August break, the SPAC market is churning out deals. Three IPOs are currently scheduled to list in the week ahead, although other small issuers may join the calendar during the week.

IPO Update: Adlai Nortye Readies $72 Million U.S. IPO
IPO Update: Adlai Nortye Readies $72 Million U.S. IPO
IPO Update: Adlai Nortye Readies $72 Million U.S. IPO
ANL
Seeking Alpha11 August 2023

Adlai Nortye Ltd. has filed for a $72 million IPO for its cancer drug development. The firm's lead candidate, AN2025, is in Phase 2 and Phase 3 trials for solid tumors and head and neck squamous cell cancer. The global market for head and neck cancer treatments is expected to reach $3.5 billion by 2030.

Cancer treatment company Adlai Nortye sets terms in IPO
Cancer treatment company Adlai Nortye sets terms in IPO
Cancer treatment company Adlai Nortye sets terms in IPO
ANL
Market Watch11 August 2023

Adlai Nortye Ltd. said late Thursday it plans to offer three million American depositary shares at an estimated price of $22 to $26 a share in its initial public offering on the Nasdaq under the symbol “ANL”.

FAQ

  • What is the primary business of Adlai Nortye American Depositary Shares?
  • What is the ticker symbol for Adlai Nortye American Depositary Shares?
  • Does Adlai Nortye American Depositary Shares pay dividends?
  • What sector is Adlai Nortye American Depositary Shares in?
  • What industry is Adlai Nortye American Depositary Shares in?
  • What country is Adlai Nortye American Depositary Shares based in?
  • When did Adlai Nortye American Depositary Shares go public?
  • Is Adlai Nortye American Depositary Shares in the S&P 500?
  • Is Adlai Nortye American Depositary Shares in the NASDAQ 100?
  • Is Adlai Nortye American Depositary Shares in the Dow Jones?
  • When was Adlai Nortye American Depositary Shares's last earnings report?
  • When does Adlai Nortye American Depositary Shares report earnings?
  • Should I buy Adlai Nortye American Depositary Shares stock now?

What is the primary business of Adlai Nortye American Depositary Shares?

Adlai Nortye American Depositary Shares (ANL) focuses on developing innovative cancer therapies. The company specializes in creating treatments for various types of cancer, aiming to improve patient outcomes through advanced research and development in oncology.

What is the ticker symbol for Adlai Nortye American Depositary Shares?

The ticker symbol for Adlai Nortye American Depositary Shares is NASDAQ:ANL

Does Adlai Nortye American Depositary Shares pay dividends?

No, Adlai Nortye American Depositary Shares does not pay dividends

What sector is Adlai Nortye American Depositary Shares in?

Adlai Nortye American Depositary Shares is in the Healthcare sector

What industry is Adlai Nortye American Depositary Shares in?

Adlai Nortye American Depositary Shares is in the Biotechnology industry

What country is Adlai Nortye American Depositary Shares based in?

Adlai Nortye American Depositary Shares is headquartered in Cayman Islands

When did Adlai Nortye American Depositary Shares go public?

Adlai Nortye American Depositary Shares's initial public offering (IPO) was on 23 September 2023

Is Adlai Nortye American Depositary Shares in the S&P 500?

No, Adlai Nortye American Depositary Shares is not included in the S&P 500 index

Is Adlai Nortye American Depositary Shares in the NASDAQ 100?

No, Adlai Nortye American Depositary Shares is not included in the NASDAQ 100 index

Is Adlai Nortye American Depositary Shares in the Dow Jones?

No, Adlai Nortye American Depositary Shares is not included in the Dow Jones index

When was Adlai Nortye American Depositary Shares's last earnings report?

Adlai Nortye American Depositary Shares's most recent earnings report was on 8 August 2024

When does Adlai Nortye American Depositary Shares report earnings?

The next expected earnings date for Adlai Nortye American Depositary Shares is 8 August 2025

Should I buy Adlai Nortye American Depositary Shares stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions